Vancouver-based AI drug discovery company AbCellera and biopharmaceutical company Incyte have collaborated to discover and develop therapeutic antibodies in oncology.
The partnership will leverage AbCellera's antibody discovery technology to accelerate the development of Incyte's preclinical pipeline of oncology medicines. Through the collaboration, Incyte will get the right to develop and commercialize the therapeutic antibodies, with AbCellera receiving research payments, milestone payments, and royalties on net sales of products.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.